The antidepressants most likely to cause weight gain are tricyclic antidepressants (like amitriptyline and nortriptyline), the MAOI phenelzine, mirtazapine, and the SSRI paroxetine. A meta-analysis of 27 cohort studies covering more than 450,000 people confirmed these as the highest-risk options. But the picture varies widely across drug classes, and some antidepressants carry little to no weight risk at all.
The Highest-Risk Antidepressants
Not all antidepressants affect weight equally. Here are the ones with the strongest links to weight gain, based on pooled clinical data:
- Amitriptyline (Elavil): A tricyclic antidepressant associated with roughly 1.5 to 2 kg (3 to 4.5 lbs) of weight gain. The risk of gaining 5% or more of your body weight is considered high.
- Nortriptyline (Pamelor): Another tricyclic with a similar profile, averaging 1.5 to 2 kg of gain.
- Phenelzine (Nardil): An MAOI linked to 2 to 3 kg (4.5 to 6.5 lbs) of gain, the highest average among commonly studied antidepressants.
- Mirtazapine (Remeron): Averages about 1.74 kg (nearly 4 lbs) in just the first 12 weeks of treatment.
- Paroxetine (Paxil): The SSRI most strongly tied to weight gain, with increases ranging from 0.37 to 2.73 kg and a 21% higher chance of clinically significant weight gain compared to other options.
Tricyclic antidepressants as a class carry enough weight risk that they’re typically avoided in people who are already overweight. MAOIs like phenelzine are rarely prescribed today for other reasons (strict dietary restrictions and drug interactions), but weight gain is another mark against them.
Why Some Antidepressants Increase Weight
The main culprit is how certain antidepressants interact with histamine receptors in the brain. Drugs that block the H1 histamine receptor, the same receptor targeted by drowsy allergy medications, reduce your feeling of fullness after eating and increase cravings for carbohydrates. The stronger a drug’s affinity for blocking H1 receptors, the more weight gain it tends to cause. This is why mirtazapine and the tricyclics, which have potent antihistamine effects, sit at the top of the risk list.
A second mechanism involves serotonin signaling. Some antidepressants block a specific serotonin pathway that normally helps suppress appetite. When that pathway is disrupted, appetite increases and caloric intake rises. These two effects, histamine blockade and serotonin disruption, often overlap in the same medications, compounding the problem.
SSRIs Are Not All the Same
SSRIs are the most commonly prescribed antidepressants, and people often assume they all carry similar weight risks. They don’t. In a head-to-head trial comparing three SSRIs over an extended treatment period, paroxetine caused significant weight gain. Sertraline produced a modest, statistically nonsignificant increase. Fluoxetine (Prozac) actually trended toward slight weight loss. The number of patients who gained more than 7% of their body weight was significantly higher on paroxetine than on either of the other two.
More broadly, SSRIs as a class tend to cause short-term weight loss followed by gradual long-term weight gain. The short-term loss likely reflects the appetite-suppressing effects that many people notice in their first weeks on an SSRI. Over months and years, though, the trend reverses. This means your experience at 3 months may look very different from your experience at 12 or 24 months.
The Timeline Matters
Weight changes from antidepressants don’t happen all at once. Mirtazapine tends to act quickly, with noticeable gain within the first 12 weeks. Tricyclics also produce relatively early changes. SSRIs follow a slower pattern, sometimes taking six months or longer before weight gain becomes apparent.
There’s also evidence that antidepressant exposure can alter weight regulation even after you stop taking the medication. Animal research has shown that short-term antidepressant use during stressful periods, followed by a high-fat diet, led to significantly higher body weight and calorie intake months after the drug was discontinued. While animal studies don’t translate directly to humans, this suggests the metabolic effects may outlast the prescription itself, particularly when combined with dietary habits that promote weight gain.
Effects Beyond the Scale
Weight gain isn’t purely cosmetic. People with depression already face a higher risk of cardiovascular disease, and adding extra weight can worsen that risk. Tricyclic antidepressants in particular have been linked to impaired blood sugar control in people with diabetes, potentially raising blood glucose and insulin levels. SSRIs, by contrast, appear to have a more favorable metabolic profile, with some evidence that they may actually improve insulin sensitivity and lower fasting blood sugar in depressed patients.
Weight gain is also one of the leading reasons people stop taking their antidepressant altogether, which creates its own set of risks. If you’re gaining weight on a medication that’s working well for your mood, that tradeoff deserves a thoughtful conversation rather than an abrupt decision to quit.
Weight-Neutral and Weight-Loss Options
Bupropion (Wellbutrin) stands alone as the only antidepressant consistently associated with weight loss rather than weight gain. Studies lasting up to 52 weeks have confirmed modest weight loss, and it has been classified as the sole “no risk” antidepressant for weight gain, with some tendency to promote weight loss in people with obesity. It works through a different mechanism than SSRIs, primarily affecting dopamine and norepinephrine rather than serotonin.
Vilazodone and vortioxetine are newer antidepressants that also appear to carry lower weight risk, though the data on them is less extensive than for bupropion. Fluoxetine, while technically an SSRI, tends to be the most weight-friendly option within that class, particularly in the first year of use.
If weight is a major concern for you, these options are worth discussing as first-line choices. For people already on a higher-risk antidepressant who are experiencing unwanted weight gain, switching to a lower-risk alternative is a common strategy, though any change should be gradual and supervised to avoid withdrawal effects or a return of depressive symptoms.